We are only able to display limited information for this firm. We display more complete information for all of the following firms:
The result of a May 2024 merger between Allen & Overy LLP and Shearman & Sterling, A&O Shearman acts for pharmaceutical, healthcare, biotech and growth-stage companies. In addition to advising on a range of transactions, including M&A, equity capital markets, licensing and collaborations, it has notable expertise in IP, dispute resolution and corporate investigations. In Shanghai, Jill Ge's assists with a broad array of IP litigation and transactions in China; and Jack Wang focuses on the pharmaceutical and medical devices industries.
Legal 500 Editorial commentary
Key clients
- Mindray Bio-Medical Electronics
- JOY Group
Abbreviated data is displayed for this firm.
Work highlights
- Acted for CBC Healthcare Infrastructure Management on securing a $300m upsize capital commitment for its life sciences infrastructure fund (with a jurisdictional focus on China) from Mubadala Investment Company.
- Advised Haleon on the divestiture of its Lamisil brand across 70-plus jurisdictions (including China) to Karo Healthcare for an aggregate consideration of £235m.
Abbreviated data is displayed for this firm.